130 years of experience. Bold in research. Focused on one thing: improving lives through science.
With our research and development pipeline, we target some of the highest-needing therapeutic areas.
In 2017, after seven years of challenging research, Dompé successfully engineered and manufactured the first recombinant human nerve growth factor (rhNGF).
Life sciences are radically improving the chances of treatment, even for diseases that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.
Redefining treatments for ophthalmic, neurological and pain-related indications through NGF and beyond. Read more on our research
The discovery of new drug molecules is pivotal to identifying novel therapeutic strategies. But drug discovery is a slow and articulated process with an extremely high failure rate. At Dompé, we have developed the virtual screening platform Exscalate to accelerate the drug screening process.
Our relentless drive to advance science and meet patients’ needs keeps us focused on what truly matters. With this commitment, we’re able to pioneer innovative treatments that transform lives—across ophthalmology, neurology and beyond.
Our values are the foundation that unites everything we do at Dompé. They express who we are as a company and guide our journey of following the science. We believe in the strength of these values to foster an inclusive culture—one where every individual feels respected, empowered, and motivated to drive innovation every day.
Stay informed with the latest updates, breaking news, and featured stories, while exploring insights from our research, initiatives, and current projects.
Explore the latest press releases and news about Dompé
Updates, information, and resources for journalists and stakeholders